Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months [Yahoo! Finance]
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months [Globe and Mail, The (Toronto, Canada)]
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting [Yahoo! Finance]